Clinical Trial Update: First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

First-in-human Phase 1 study of IBI308 in Chinese subjects with advanced solid tumors has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Solid Tumors

Drugs mentioned

• IBI308 (IBI308)

Snippet

Sponsor: Innovent Biologics (Suzhou) Co. Ltd. | Conditions: Cancer, Solid Tumor | Phase 1 | Status: COMPLETED | Results posted: 2021-02-21